Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMAB806 for cytokine release syndrome in COVID-19
ChiCTR2000030196Phase 2Not yet recruiting
- Sponsor
- Zhongnan Hospital of Wuhan University
- Start
- Feb 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tocilizumab in cytokine release syndrome (CRS) and coronavirus disease 2019 (COVID-19), sponsored by Zhongnan Hospital of Wuhan University. Primary endpoint: CRS relief rate. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
tocilizumab
03
Conditions
cytokine release syndrome (CRS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000030196.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030196.